Search Results
Your search for ,OUr matches 10724 pages
Showing 6601 - 6650More Patients With Early-Stage Breast Cancer May Be Able to Avoid Chemotherapy in the Future
Women with early-stage breast cancer who had an intermediate risk recurrence score from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds. The research, published by Barcenas et al in ...
ASCO-SITC Clinical Immuno-Oncology Symposium: Response to Cancer Immunotherapy May Depend on Gut Bacteria
Researchers have found a link between microbes in the gut (the microbiome) and response to immunotherapy. In the study, the ability of patients with advanced melanoma to respond to programmed cell death protein 1 (PD-1) immune checkpoint inhibitors depended on the presence of a diverse microbiome...
2017 GU Cancers Symposium: Updated Efficacy and Tolerability of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
At the 2017 Genitourinary Cancers Symposium, Powles et al presented updated efficacy and safety data for durvalumab in patients with locally advanced or metastatic urothelial cancer (Abstract 286). Updated results from the phase I/II trial showed an objective response rate of 20.4% in all...
Optimal Time to Assess Response After Chemoradiotherapy in Anal Squamous Cell Carcinoma
In a post hoc analysis of the UK ACT II trial reported in The Lancet Oncology, Glynne-Jones et al found that the best time to assess for complete response to chemoradiotherapy in patients with anal squamous cell carcinoma is at approximately 26 weeks from the start of treatment. In the ACT II...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Many Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey, Guildford, United Kingdom, have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, according to a recent study reported by Anna Cox,...
New Lung Cancer Staging Manual Set to Modify Clinical Practice
A revised tumor classification based on 70,967 evaluable patients with non–small cell lung cancer (NSCLC) and 6,189 patients with small cell lung cancer is now available to lung cancer specialists around the world in the form of the 8th edition of the tumor, node, and metastasis (TNM)...
Combination Immunotherapy for Lung Cancer: The Wave of the Future
Increasing experience with immunotherapy for lung cancer in both the lab and the clinic is helping to refine treatment approaches and point the way forward, according to Naiyer Rizvi, MD, Director of both Thoracic Oncology and Immunotherapeutics at Columbia University Medical Center in New York....
Elisabeth Heath, MD, FACP, Appointed Associate Center Director for Translational Sciences at Karmanos
Elisabeth Heath, MD, FACP, of the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has been appointed Associate Center Director for Transitional Sciences, effective immediately. She will report to Gerold Bepler, MD, PhD, President and Chief Executive Officer of...
New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS
The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,500 physicians, researchers, and other health-care professionals from over 90 countries. Through...
Expert Point of View: Paul Mitchell, MD
“The progression-free and overall survival curves of CheckMate 057 suggest the presence of two patient populations with respect to nivolumab (Opdivo): a relatively sensitive one and a less sensitive, possibly even resistant, one, according to invited discussant Paul Mitchell, MD, Associate...
New Analysis of CheckMate 057: Search Continues for Predictors of Outcome With Nivolumab
Prognostic factors and tumor expression of programmed cell death ligand 1 (PD-L1) predict early mortality among patients with previously treated nonsquamous advanced non–small cell lung cancer (NSCLC) who receive nivolumab instead of docetaxel. But these features are not reliable for excluding...
KEYNOTE-010 Update Shows ‘Striking’ Durability of Second-Line Pembrolizumab in NSCLC
Pembrolizumab’s benefit in previously treated advanced non–small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1) is long lasting, persisting even after therapy ends, suggests an update of the KEYNOTE-010 trial.1 Initial results of the randomized phase II/III trial,...
Expert Point of View: Michael Boyer, MBBS, PhD
“This was a very nice analysis using a well-validated group of instruments with high compliance. And this is something that is one of the bugbears of quality-of-life analyses—compliance to completion of the instruments,” commented invited discussant, Michael Boyer, MBBS, PhD, Chief Clinical Officer ...
Expert Point of View: Edward B. Garon, MD
“There are several possible ways to move first-line immunotherapy for non–small cell lung cancer (NSCLC) forward, according to invited discussant Edward B. Garon, MD, Director of Thoracic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles. “We could expand...
Expert Point of View: Philip B. Paty, MD
Philip B. Paty, MD, a surgical oncologist at Memorial Sloan Kettering Cancer Center, New York, commented on the findings for The ASCO Post. Dr. Paty is leading studies of surveillance at his own institution, which is not part of the International Watch & Wait Database. Consistency of Outcomes...
‘Watch-and-Wait’ Strategy Does Not Compromise Survival in Selected Patients With Rectal Cancer
A “watch-and-wait” approach to treating rectal cancer patients with complete responses to chemoradiotherapy resulted in a 3-year survival rate of 91%, which is similar to historic survival rates after surgical resection, according to an analysis of the International Watch & Wait Database.1 For ...
Timing Is Everything
In 1959, my 5-year-old cousin, Kim, was diagnosed with acute lymphocytic leukemia (ALL). As an 8-year-old, I didn’t really understand what was happening to him, except that he had to go to the Riley Hospital for Children in Indianapolis, Indiana, for treatment. The haunting vision of his looking...
Understanding the Role of Immunotherapy for Lung Cancer: A Paradigm Shift for the Better
“Immunotherapy for lung cancer is a paradigm shift. I would never have thought when I started my career taking care of lung cancer patients in the mid 1990s that we’d now be substituting chemotherapy with an antibody immunotherapy in 2017. It’s incredible,” commented Roy S. Herbst, MD, PhD, Chief...
CheckMate 142 Update: Prolonged Disease Control With Nivolumab in Deficient Mismatch Repair Colorectal Cancer
With 6 additional months of follow-up since the initial presentation of results, in the phase II CheckMate 142 trial, 74% of heavily pretreated patients with metastatic colorectal microsatellite instability–high (MSI-H) cancers are alive after single-agent treatment with nivolumab (Opdivo).1...
Protein Component of the Epstein-Barr Virus May Promote the Development of Cancer
After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms. About one-third of infected teenagers and young adults nevertheless develop infectious mononucleosis, which usually wears off after a few weeks. ...
Never Smokers Account for Increased Proportion of Non–Small Cell Lung Cancer Cases
In a retrospective study in three U.S. institutions reported in the Journal of the National Cancer Institute, Pelosof et al found that never smokers accounted for an increasing proportion of cases of non–small cell lung cancer (NSCLC) during the period from 1990 to 2013. The study used data...
Combination of Alisertib and HSV1716 Shows Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor and Neuroblastoma Models
Two investigational agents, the aurora A kinase inhibitor alisertib and a virus derived from HSV-1 (HSV1716), have shown antitumor efficacy in early clinical trials as monotherapies. A new study published by Currier et al in Oncotarget, however, demonstrates that the combined usage...
Disease Symptoms Are the Most Frequent Indicators of Recurrence in Patients With Stage II Melanoma
Recurrences of early-stage (stage II) melanoma are more often detected by patients and their physicians than by routine imaging tests, according to study results published by Berger et al in the Journal of the American College of Surgeons. “We are most concerned about patients who have stage ...
2017 GU Cancers Symposium: Some Patients With Renal Cell Carcinoma Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early
Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy—continuing treatment until cancer worsens. Among patients with advanced kidney cancer who stopped programmed cell death protein 1/programmed cell death ligand 1...
Clinical Trial Explores Ability of Genetic Test to Guide Surgical Management of Thyroid Cancer
University of Pittsburgh School of Medicine scientists and doctors are embarking on the first clinical trial to determine if a genetic test they pioneered could successfully spare patients with nonaggressive thyroid cancer from complete removal of their thyroid. Thyroid-preserving surgery minimizes ...
Patients With Breast Cancer With Dense Breast Tissue More Likely to Develop Contralateral Disease
Patients with breast cancer with dense breast tissue have almost a twofold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer Center. The study, published by Brewster et al in the journal Cancer, is among the...
Most Patients Undergoing Elective Colorectal Surgery Receive Inadequate Bowel Preparation to Prevent Postoperative Complications
In the largest study of its kind to date, researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University confirmed that oral antibiotics combined with mechanical bowel preparation were more effective at preventing surgical site infections...
Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, a new study by Cox et al in the Journal of Medical Internet...
Children, Parents Overreport Leukemia Treatment Adherence
New research suggests that young patients with acute lymphocytic leukemia (ALL) and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in Blood, found that 84% of patients with ALL...
Residual Cancer Burden, Breast Cancer Phenotype, and Long-Term Prognosis After Neoadjuvant Chemotherapy
In a study reported in the Journal of Clinical Oncology, Symmans et al found that residual cancer burden (RCB) after neoadjuvant chemotherapy was significantly prognostic for long-term outcome across breast cancer subtypes. Study Details The study included 5 patient cohorts from The University of ...
Justin F. Klamerus, MD, MMM, Appointed President of Karmanos Cancer Hospital
Justin F. Klamerus, MD, MMM, has been appointed President of the Barbara Ann Karmanos Cancer Hospital, the clinical operation of Karmanos Cancer Institute in Detroit. The appointment was effective as of January 2017. Dr. Klamerus will report directly to Gerold Bepler, MD, PhD, President and Chief...
Postinduction MRD Predicts Outcome From Transplantation in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). Nicolas...
Kerry and Simone Vickar Family Foundation Commits $2 Million for Levine Cancer Institute Hematologic Oncology Chair
Carolinas HealthCare System has announced a $2 million commitment from the Kerry and Simone Vickar Family Foundation in support of academic and research efforts at the Levine Cancer Institute in Charlotte, North Carolina. The funds will be designated to establish an endowed chair in their name: The ...
‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...
Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma
Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...
Circulating Tumor DNA Profiling Identifies Clonal Evolution Patterns and Permits Classification of Tumor Subtypes in DLBCL
In a study reported in Science Translational Medicine, Florian Scherer, MD, David M. Kurtz, MD (Conquer Cancer Foundation Young Investigator), Aaron M. Newman, PhD, and colleagues from Stanford University found that analysis of circulating tumor DNA (ctDNA) permits identification of patterns of...
On the Horizon: New Tools for Prostate Cancer
The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change clinical...
Women of Indigenous Communities Prefer Self-Screening for Cervical Cancer
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities. A new study by the University of Michigan published by Gottschlich et al in the Journal of...
Low Prostate Cancer–Specific Mortality in Men With Benign Initial Transrectal Ultrasound–Guided Biopsy Sets
In a Danish study reported in The Lancet Oncology, Klemann et al found a low risk of prostate cancer–specific mortality in men with benign initial transrectal ultrasound-guided biopsy sets. The risk was particularly low among those with lower prostate-specific antigen (PSA) levels. Study...
From Azerbaijan to America: An IDEA Recipient’s Experience
Cancer takes away millions of lives every year, and in low- and middle-income countries, the high cancer mortality rate can often be attributed to scarce means and a shortage of trained professionals. Hoping to contribute my best in the fight against this disease, I chose to become an oncologist in ...
Expert Point of View: Steven D. Gore, MD, and Rami Komrokji, MD
Steven D. Gore, MD, Director of Hematologic Malignancies at Yale School of Medicine, New Haven, Connecticut, applauded Dr. Stein for “accruing a terrible patient population, mutation-wise” and called the preliminary findings for the benefit of enasidenib in patients with ASXL1 mutations...
Studies Advance the Use of PD-1 Blockade in Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory...
Expert Point of View: Amber Orman, MD
Amber Orman, MD, of the Department of Radiation Oncology, Breast Section, at Moffitt Cancer Center in Tampa, Florida, who was not involved in this study, said: “This study provides guidance when deciding how best to integrate postmastectomy reconstruction and radiation therapy. This is an area...
Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD
Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...
ECCO 2017: Pembrolizumab Shows Activity in Mucosal Melanoma in Multiple KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO) (Abstract 1142). Until now, mucosal melanoma has often...
Tumor-Infiltrating Lymphocytes Prognostic in the Metastatic and Neoadjuvant Breast Cancer Settings
Studies presented at the 2016 San Antonio Breast Cancer Symposium added to growing evidence that tumor-infiltrating lymphocytes are important prognostic factors in breast cancer. One investigation evaluated their impact in advanced HER2-positive breast cancer, finding a linear relationship between...
The Cost of a Patient’s Last Ride
It was a call from a referring physician who wanted the patient to be transferred to our major academic center. The patient had a history of a lethal malignancy in a very advanced stage. The patient was already outside the bell curve, for she had survived far longer than expected for a malignancy...
Expert Point of View: Frank A. Sinicrope, MD
Frank A. Sinicrope, MD, Professor of Medicine and Oncology at the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that the regimen of irinotecan/cetuximab (Erbitux)/vemurafenib (Zelboraf) could be an important approach to treating this challenging tumor subtype. “BRAF-mutated tumors have a...
Dual Inhibition Proves Effective for BRAF-Mutated Colorectal Tumors
In patients with metastatic colorectal cancer who have mutations in BRAF V600, the addition of the BRAF inhibitor vemurafenib (Zelboraf) to cetuximab (Erbitux) and irinotecan significantly improved progression-free survival, results of the phase II Southwest Oncology Group (SWOG) 1406 trial have...
